Publication Title: 
Cancer Investigation

Paclitaxel is an active agent for adenocarcinomas and squamous cell carcinomas of the esophagus and is a radiation sensitizer. We sought to investigate the toxicity and complete response rate of paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Forty-one patients with esophageal cancer were studied, 29 with adenocarcinomas and 12 with squamous cell cancers. Twelve patients had tumor extension into the proximal stomach and/or abdominal adenopathy.

Safran, H.
Gaissert, H.
Akerman, P.
Hesketh, P. J.
Chen, M. H.
Moore, T.
Koness, J.
Graziano, S.
Wanebo, H. J.
Subscribe to RSS - Esophagitis